Natera Panorama analyzes cell-free DNA that largely comes from the placenta, not directly from the fetus. If placental cells have a chromosome difference that the fetus doesn’t share, screening may show a false positive. Learn why confirmatory testing can help clarify the result.

Multiple Choice

False positives in cfDNA testing can result from mosaicism confined to the placenta.

False positives in cfDNA testing can result from mosaicism confined to the placenta. cfDNA screening analyzes DNA fragments circulating in maternal blood, and most of these fragments come from placental cells. If there is mosaicism confined to the placenta—where some placental cells have aneuploidy while the fetus is euploid—the test will reflect the placental abnormality. This can yield a positive result for aneuploidy even though the fetus does not have the condition. That’s why placental mosaicism is a recognized cause of false positives, and any positive cfDNA result is typically followed by diagnostic testing (such as amniocentesis or CVS) to confirm fetal karyotype.

Why Placental Mosaicism Can Affect Natera Panorama Results

A blood sample taken during pregnancy can reveal important clues about a fetus’s chromosomes. But the DNA fragments measured by cell-free DNA screening don’t come mainly from the fetus. Most come from the placenta, an organ that supports the pregnancy and shares much of the fetus’s genetic makeup. That close connection makes screening possible—and it also creates a few surprising complications.

One of them is confined placental mosaicism. When this occurs, some placental cells have a chromosome difference while the fetus does not. Because a screening test such as Natera Panorama reads DNA released by the placenta, the result may suggest a fetal chromosome condition that isn’t present in the fetus. In other words, placental mosaicism can contribute to a false-positive result.

The placenta leaves a genetic trail

Cell-free DNA, often shortened to cfDNA, refers to tiny pieces of DNA that circulate in a pregnant person’s blood. Some of these fragments come from the pregnant person, and a portion come from placental cells. That placental contribution is sometimes called the fetal fraction, even though it comes from the placenta rather than directly from the fetus.

Panorama analyzes this DNA signal to estimate the chance of certain chromosome conditions. It is a screening test, not a diagnosis. That distinction matters. Screening looks for patterns that raise or lower the likelihood of a condition; diagnostic testing examines fetal or placental cells more directly.

The placenta and fetus usually have the same chromosome makeup, so placental DNA can offer useful information about fetal chromosomes. Usually is doing important work in that sentence, though. Early in development, cells divide and specialize. If a chromosome error occurs in one cell, it may be passed on to some of its descendants but not others. The result can be a mix of cells with different chromosome patterns, known as mosaicism.

What “confined to the placenta” means

In confined placental mosaicism, the chromosome difference is found in placental cells but not in the fetus. The placenta may contain a mixture: some cells have the usual number of chromosomes, while others have an extra or missing chromosome. Meanwhile, the fetus may have a typical chromosome pattern.

Imagine the placenta as a large choir, with each section representing a different group of cells. If one section sings a different note, a recording of the whole choir may pick up that variation—even if the lead singer, representing the fetus, sings the expected tune. It’s not a perfect comparison, but it captures the key point: the sample reflects placental DNA, and the placenta may not always match the fetus exactly.

If placental cells carry an extra chromosome, their DNA fragments can influence the signal in maternal blood. Panorama may then report a higher chance of a related chromosome condition. Yet the fetus may not have that condition. This is one reason a positive screening result should not be treated as a confirmed diagnosis.

Why screening and diagnosis can differ

A positive cfDNA result means the screening pattern is associated with an increased likelihood of a chromosome condition. It does not tell, on its own, whether the chromosome difference is present in the fetus, the placenta, or both. Other factors can also affect a result, including a vanished twin, differences in the pregnant person’s chromosomes, and technical or biological limits of the test.

The chance that a positive result reflects a fetal condition varies with the specific finding and the pregnancy’s circumstances. A result for one condition may have a different likelihood of being confirmed than a result for another. Age and the starting likelihood of a condition can also shape how a result is understood. So a report needs context, not just a glance at a number.

When a screening result is positive, clinicians may discuss diagnostic testing and other follow-up steps. Amniocentesis samples cells from the fluid around the fetus and can help assess the fetal chromosome pattern. Chorionic villus sampling (CVS) collects placental tissue, so it may be useful but can be harder to interpret when placental mosaicism is suspected. The choice of follow-up depends on the result, timing, medical history, and the care team’s guidance.

This difference between samples is easy to miss. If the concern is that the placenta has a chromosome pattern the fetus does not share, another sample of placental tissue may not fully settle the question. A clinician or genetic counselor can explain which approach is most informative in a particular situation.

What a result can—and can’t—say

Panorama can provide valuable information, but no screening test can capture every detail of a pregnancy. A low-risk result does not guarantee that a fetus has no chromosome or health condition. A high-risk result does not prove that a condition is present. These tests are designed to estimate likelihood, not to replace diagnostic evaluation.

It can help to think of cfDNA screening as a signal rather than a verdict. A strong signal deserves attention, but the source still needs to be understood. In the case of confined placental mosaicism, the signal may be real: the placenta may indeed have cells with an altered chromosome pattern. The mismatch lies in what that signal says about the fetus.

That’s also why the term “false positive” can feel a little misleading. The result may not be false about the placenta; it may simply not describe the fetal chromosomes accurately. Still, in clinical language, a result is generally considered a false positive when screening indicates a condition that diagnostic testing does not find in the fetus.

Why careful follow-up matters

A positive result can bring worry, especially when the report arrives before there is a clear explanation. Genetic counseling can help translate the findings into plain language, discuss the limits of screening, and review possible next steps. It can also help families understand how the type of chromosome finding and the choice of diagnostic sample may affect interpretation.

Confined placental mosaicism may matter beyond screening, too. In some pregnancies, placental chromosome differences are associated with concerns about growth or placental function, though the significance depends on the specific situation. A healthcare team can advise whether additional monitoring is appropriate.

The central idea is straightforward: cfDNA screening reads DNA fragments that largely come from the placenta. If some placental cells have a chromosome difference that the fetus does not share, the result may point toward a condition in the fetus when it is actually confined to the placenta. That is a recognized source of false positives, and it explains why screening results are interpreted as part of a broader clinical picture—not as a diagnosis by themselves.